Patents by Inventor Robert S. Galen

Robert S. Galen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combined assay for current glucose level and intermediate or long-term glycemic control
    Patent number: 6958129
    Abstract: The present invention is directed to a single test system and method for determining the integrated glycemic condition of a subject by measuring the concentration of glucose and the level of protein-bound glucose in a subject's body fluid, such as whole blood. The glucose concentration is indicative of the subject's immediate glycemic condition, whereas the protein-bound glucose concentration is indicative of either intermediate or long-term glycemic condition. Optionally, other analytes indicative of glycemic condition, such as ketone bodies or fatty acid derivatives, can also be measured. The present invention also provides a method of diagnosing diabetes. The invention additionally provides a method for analyzing the concentration of fructosamine in less than or equal to five minutes without the use of a reaction accelerator.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: October 25, 2005
    Assignee: LifeScan, Inc.
    Inventors: Robert S. Galen, John F. Burd, Talei Hoblitzell, Gebhard Neyer
  • COMBINED ASSAY FOR CURRENT GLUCOSE LEVEL AND INTERMEDIATE OR LONG-TERM GLYCEMIC CONTROL
    Publication number: 20040265941
    Abstract: The present invention is directed to a single test system and method for determining the integrated glycemic condition of a subject by measuring the concentration of glucose and the level of protein-bound glucose in a subject's body fluid, such as whole blood. The glucose concentration is indicative of the subject's immediate glycemic condition, whereas the protein-bound glucose concentration is indicative of either intermediate or long-term glycemic condition. Optionally, other analytes indicative of glycemic condition, such as ketone bodies or fatty acid derivatives, can also be measured. The present invention also provides a method of diagnosing diabetes. The invention additionally provides a method for analyzing the concentration of fructosamine in less than or equal to five minutes without the use of a reaction accelerator.
    Type: Application
    Filed: September 19, 2003
    Publication date: December 30, 2004
    Inventors: Robert S. Galen, John F. Burd, Talei Hoblitzell, Gebhard Neyer
  • Apparatus for combined assay for current glucose level and intermediate or long-term glycemic control
    Patent number: 6670192
    Abstract: The present invention is directed to a single test system and method for determining the integrated glycemic condition of a subject by measuring the concentration of glucose and the level of protein-bound glucose in a subject's body fluid, such as whole blood. The glucose concentration is indicative of the subject's immediate glycemic condition, whereas the protein-bound glucose concentration is indicative of either intermediate or long-term glycemic condition. Optionally, other analytes indicative of glycemic condition, such as ketone bodies or fatty acid derivatives, can also be measured. The present invention also provides a method of diagnosing diabetes. The invention additionally provides a method for analyzing the concentration of fructosamine in less than or equal to five minutes without the use of a reaction accelerator.
    Type: Grant
    Filed: January 5, 2000
    Date of Patent: December 30, 2003
    Inventors: Robert S. Galen, John F. Burd, Talei Hoblitzell, Gebhard Neyer
  • Apparatus for combined assay for current glucose level and intermediate or long-term glycemic control
    Patent number: 6027692
    Abstract: The present invention is directed to a single test system and method for determining the integrated glycemic condition of a subject by measuring the concentration of glucose and the level of protein-bound glucose in a subject's body fluid, such as whole blood. The glucose concentration is indicative of the subject's immediate glycemic condition, whereas the protein-bound glucose concentration is indicative of either intermediate or long-term glycemic condition. Optionally, other analytes indicative of glycemic condition, such as ketone bodies or fatty acid derivatives, can also be measured. The present invention also provides a method of diagnosing diabetes. The invention additionally provides a method for analyzing the concentration of fructosamine in less than or equal to five minutes without the use of a reaction accelerator.
    Type: Grant
    Filed: December 12, 1996
    Date of Patent: February 22, 2000
    Assignee: LXN Corporation
    Inventors: Robert S. Galen, John F. Burd, Talei Hoblitzell, Gebhard Neyer
  • Combined assay for current glucose level and intermediate or long-term glycemic control
    Patent number: 5695949
    Abstract: The present invention is directed to a single test system and method for determining the integrated glycemic condition of a subject by measuring the concentration of glucose and the level of protein-bound glucose in a subject's body fluid, such as whole blood. The glucose concentration is indicative of the subject's immediate glycemic condition, whereas the protein-bound glucose concentration is indicative of either intermediate or long-term glycemic condition. Optionally, other analytes indicative of glycemic condition, such as ketone bodies or fatty acid derivatives, can also be measured. The present invention also provides a method of diagnosing diabetes. The invention additionally provides a method for analyzing the concentration of fructosamine in less than or equal to five minutes without the use of a reaction accelerator.
    Type: Grant
    Filed: April 7, 1995
    Date of Patent: December 9, 1997
    Assignee: LXN Corp.
    Inventors: Robert S. Galen, John F. Burd, Talei Hoblitzell, Gebhard Neyer